yahoo_financeOriginal article
AGIO Shares Sink Nearly 7% After Scrapping the Tebapivat SCD Program
negativeTebapivatNegative
AI Analysis
Summary
Agios Pharmaceuticals discontinued its Tebapivat program for sickle cell disease, resulting in a nearly 7% decline in AGIO share price. The program termination represents a setback to the company's pipeline.
Outcome Details
Program discontinued
Importance:6/10
Sentiment:
-0.80
program discontinuationsickle cell diseasestock declinepipeline update
Related Companies
Read the original article
Published by yahoo_finance on July 22, 2026 4:22 PM